N/A N=27 Evaluation of Atorvastatin on Atherosclerosis Composition
Atherosclerosis
Primary: Change in Necrotic Core Volume — 0.07 mm^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=179 Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI)
Coronary Arteriosclerosis · Arteriosclerosis, Coronary · Atherosclerosis, Coronary
Primary: Mean Coronary Wall Thickness — 2.0 mm
Phase 4 N=217 Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication
Coronary Artery Disease · Carotid Artery Diseases · Atherosclerosis
Primary: Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI — -4.6; -15.1; -9.4 mm^3/year
Phase 2 N=81 Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
Coronary Artery Disease · Human Immunodeficiency Virus
Primary: Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks — 8.1; 13.4 Percent change from rest measurement
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
Phase 3 N=55 Effect of Evolocumab on Coronary Atherosclerosis
Cardiovascular Disease · Hyperlipidemia
Primary: Change in Noncalcified Coronary Artery Plaque Volume (NCPV) — -45 mm^3
Phase 2 N=130 A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
Coronary Heart Disease
Primary: Percent Change From Baseline in Mean Wall Thickness — 4.245; 6.679 Percent Change
Phase 2 N=94 Inflammation and Coronary Endothelial Function
Coronary Artery Disease
Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
Phase 2 N=10 Rilonacept to Improve Artery Function in Patients With Atherosclerosis
Coronary Artery Disease · Atherosclerosis · Inflammation
Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L
N/A N=306 Data Acquisition for Optimization of Coronary Artery Disease (CAD) Algorithm
Coronary Artery Disease
Primary: The Area Under the Receiver Operating Characteristic Curve of the CAD-score to Separate CAD From Non-CAD Patients. — 73.4 percentage of 100
N/A N=116 COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.
Aortic Stenosis · Coronary Artery Disease
Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio
Phase 2 N=20 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
Myocardial Ischemia
Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1
N/A N=120 Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging
Coronary Disease
Primary: Ability to Detect Stress-induced Myocardial Perfusion Abnormalities by Analysis of MDCT Images Confirmed by Coronary Angiography and/or SPECT. — 78 % accurately detected…
Phase 3 N=652 Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Coronary Artery Disease (CAD) · Coronary Atherosclerosis
Primary: Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment — -0.33; 0.11 percentage of baseline
N/A N=1,271 The Lipid-Rich Plaque Study
Coronary Artery Disease · Atherosclerosis
Primary: Number of Participants Stratified as Non-Index Culprit Lesion Related Major Adverse Cardiac Events (NC-MACE) or No NC-MACE and Association With maxLCBI4mm as a…
Phase 4 N=65 Effect of Aged Garlic Extract on Atherosclerosis
Metabolic Syndrome
Primary: CT Angiography Plaque — 0.17; -1.53 percent change of low attenuation plaque
Phase 4 N=230 Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
Atherosclerosis · Hypercholesterolemia
Primary: Change in Mean of Wall Volume of Internal Carotid Arteries — -3.52; -5.91 Other - mm^3 ( cubic millimeter )
Phase 4 N=80 Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy
Hypertriglyceridemia
Primary: Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points — -0.3; 0.9 volume in mm cubed
N/A N=21 PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
Coronary Artery Disease
Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries
N/A N=900 Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
Coronary Artery Disease
Primary: Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina — 34; 28 Participants
Phase 4 N=214 Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
Hypercholesteremia
Primary: Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV) — 14.1 Percent Change
N/A N=10 Evaluation of Coronary Artery Calcification Using Gated Stationary Chest Tomosynthesis
Coronary Artery Disease
Primary: Comparison of CT Derived CACS and Tomosynthesis Scores Correlation
N/A N=45 Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury
Spinal Cord Injuries · Heart Diseases
Primary: Percent Agreement Between Coronary Calcium Score (CCS) and National Cholesterol Education Program (NCEP) Guidelines — 18 percent agreement
Phase 2 N=19 Effect of Evolocumab on Coronary Endothelial Function
Human Immunodeficiency Virus · Coronary Artery Disease
Primary: Coronary Endothelial Function as Assessed by Percent Coronary Artery Area Change With Isometric Handgrip Exercise — 5.6 percent change in coronary artery area
N/A N=80 Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial Infarction · No-Reflow Phenomenon
Primary: Hospital Mortality Rate — 6; 2 Participants
Phase 2 N=30 Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients
Atrial Fibrillation · Coronary Artery Disease
Primary: Sensitivity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD) — 80 Percentage of true positive cases
Phase 2 N=91 YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Obstructive Coronary Artery Disease · Coronary Artery Disease
Primary: Correlation Between Plaque Morphology and HDL Functionality — 0.30 beta coefficient
Phase 4 N=137 Effect of Evolocumab on Coronary Plaque Characteristics
Coronary Artery Disease
Primary: Change in Minimal Fibrous Cap Thickness (FCT) — 70.9; 97.7 µm
Phase 4 N=548 Stop Atherosclerosis in Native Diabetics Study
Cardiovascular Disease · Hypertension · Hyperlipidemia
Primary: Changing LDL Cholesterol — 100; 70 Mg/dl